<DOC>
	<DOCNO>NCT00095654</DOCNO>
	<brief_summary>The purpose study determine ramipril and/or rosiglitazone prevent onset type 2 diabetes .</brief_summary>
	<brief_title>The DREAM ( Diabetes Reduction Assessment With Ramipril Rosiglitazone Medication ) Trial</brief_title>
	<detailed_description>The DREAM trial large , international , multi-centre , randomized double-blind control trial . A total least 4000 participant impair glucose tolerance ( IGT ) 1000 participant isolate impaired fasting glucose ( IIFG ) recruit major international centre 18 month period . They randomly allocate either ramipril and/or rosiglitazone use 2X2 factorial design follow least 3 year randomization . Participants assess regular interval ascertain occurrence primary outcome ( new onset diabetes mellitus cause mortality ) secondary outcome . A diagnosis diabetes make 2 consecutive plasma glucose level exceed diagnostic threshold ( i.e . fast plasma glucose &gt; =7.0 mmol/l ( 126 mg/dl ) 2 hr plasma glucose &gt; =11.1 mmol/l ( 200 mg/dl ) ) within 3 month period . Assuming annual event rate 5 % , sample size provide 90 % power detect 22 % reduction rate primary outcome . Potential Significance Study : This study could provide new strategy prevention type 2 diabetes well provide insight relationship cardiovascular disease diabetes . Study Update : A total 5269 participant enrol study . 4527 Participants IGT 739 participant IIFG . The study currently follow-up phase . DREAM On In order determine whether benefit observe active phase trial sustain cessation active medication use , follow-up DREAM cohort conduct passive DREAM ObservatioN ( DREAM On ) follow-up study . DREAM On ass approximately 1500 consent DREAM participant without diagnosis diabetes end washout phase post-trial period 1 2 year determine effect on-trial exposure rosiglitazone and/or exposure ramipril : ) primary outcome ( incident diabetes death ) ; b ) regression maintenance normoglycemia . Participants free take medication indicate may participate research study , accord judgment physician .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>impaired glucose tolerance ( FPG &lt; 7 mmol/L 126 mg/dL AND 2 hr PG &gt; = 7.8 mmol/L &lt; 11.1 mmol/L ( 140 mg/dL &lt; 200 mg/dL ) , isolate impaired fasting glucose ( FPG &gt; = 6.1 mmol/L &lt; 7 mmol/L ( FPG &gt; = 95 mg/dL &lt; 126 mg/dL ) AND 2 hr PG &lt; 7.8 mmol/L ( 140 mg/dL ) . current use ACEinhibitor ( ACEI ) thiazolidinedione ( TZD ) know hypersensitivity ACEI prior use antidiabetic medication ( exception pregnancy ) use systemic glucocorticoid niacin congestive heart failure EF &lt; 40 % exist cardiovascular disease ( previous MI , stroke , angina , uncontrolled hypertension ) diabetes renal hepatic disease major illness use another experimental drug pregnant unwilling use reliable contraception major psychiatric disorder disease affect glucose tolerance unwillingness randomize sign inform consent know uncontrolled substance abuse inability communicate research staff</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>diabetes prevention</keyword>
	<keyword>ramipril</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>isolate impaired fasting glucose</keyword>
	<keyword>Isolated Impaired Glucose Tolerance</keyword>
</DOC>